BlossomHill Therapeutics, Inc. BLSM

IPO NASDAQ
IPO Score
IPO Date
Aug 06, 2026
Recommendation
Dividend Power Score
Day's Range
$15.61$16.94
Latest Close
Volume
--
Avg Vol (90D)
--
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
Corporate Info
Phone Number
(858) 732-3880
Address
10255 Science Center Drive
Suite 200
San Diego, CA 92121
Country
United States
Year Founded
2020
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
69
Business Description
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.